Biotechnology company Tenaya Therapeutics closed its underwritten public offering at USD 75 million, consisting of 22.6 million common shares at USD 2.6 per share, via an underwritten public offering. The gross proceeds also include pre-funded warrants as an alternative to common stock, allowing investors to purchase up to 6.2 million shares at a per-share exercise price of USD 0.001 lower than the public offering price.
Joint book-running managers of the offering include Morgan Stanley and Piper Sandler while co-lead managers for the offering were H.C. Wainwright & Co. and Chardan.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.